⚡️⚡️⚡️
With energy prices rising, switch to a cheaper plan
💡
Compare Prices Now
⚡️⚡️⚡️

How to buy Gilead Sciences (GILD) shares in Australia

Learn how to easily invest in Gilead Sciences shares.

We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!

Gilead Sciences Inc (GILD) is a leading drug manufacturers-general business with stocks listed in the US. It opened the day at US$62.77 after a previous close of US$63.08. During the day the price has varied from a low of USD62.63 to a high of USD63.53. The latest price was USD62.83 (25 minute delay). Gilead Sciences is listed on the NASDAQ. All prices are listed in US Dollars.

How to buy shares in Gilead Sciences

  1. Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Gilead Sciences. Find the share by name or ticker symbol: GILD. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Gilead Sciences reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of US$63.08, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Gilead Sciences, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Gilead Sciences. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Gilead Sciences stock price (NASDAQ:GILD)

Use our graph to track the performance of GILD stocks over time.

Gilead Sciences shares at a glance

Information last updated 2022-06-27.
OpenUS$62.77
HighUS$63.53
LowUS$62.63
CloseUS$62.83
Previous closeUS$63.08
Change US$-0.25
Change % -0.3963%
Volume 6,308,622
Information last updated 2022-06-27.
52-week rangeUS$55.9001 - US$72.2839
50-day moving average US$62.0314
200-day moving average US$65.4829
Target priceUS$69.21
PE ratio 17.6201
Dividend yield US$2.86 (4.63%)
Earnings per share (TTM) US$3.58

Compare trading apps to buy Gilead Sciences shares

1 - 7 of 7
Name Product Standard brokerage for US shares Currency conversion fee Markets
eToro (global stocks)
US$0
50 pips (US$0.50 for every AU$100 exchanged)
Global shares, US shares, ETFs
Zero brokerage share trading on US, Hong Kong and European stocks with trades as low as $50.
Note: This broker offers CFDs which are volatile investment products and most clients lose money trading CFDs with this provider.
Join the world’s biggest social trading network when you trade stocks, commodities and currencies from the one account.
IG Share Trading
US$0
0.70%
ASX shares, US shares, UK shares, ETFs, and more
Exclusive: Finder customers who apply for a share trading account in June will be able to trade Aussie shares from $2.50 commission until the end of August. T&Cs apply.
Enjoy some of the lowest brokerage fees on the market when trading Australian shares, international shares, plus get access to 24-hour customer support.
Tiger Brokers
Exclusive
Tiger Brokers
US$1.99
N/A
ASX shares, Global shares, Options trading, US shares, ETFs
Exclusive to Finder: Sign up to Tiger through Finder and on completion of your first deposit of any amount or transfer of shares receive 4 extra free grab shares. T&Cs apply.
Get started with $0 brokerage on ASX and US stocks for the first 3 months upon completion of your first qualifying deposit. Also receive a free Apple share if you deposit $3,000 or more.
SelfWealth (Basic account)
US$9.5
0.60%
ASX shares, US shares
Trade ASX and US shares for a flat fee of $9.50, regardless of the trade size.
New customers receive free access to Community Insights with SelfWealth Premium for the first 90 days. Follow other investors and benchmark your portfolio performance.
Bendigo Invest Direct
$0
0.60%
ASX shares, Global shares, Options trading, mFunds, ETFs, Warrants
Gain access to 12 markets from one account with Bendigo.
Invest in Australian shares and access major international markets through a trusted local brand. Plus, fine tune your investment knowledge with Bendigo’s advanced research and analysis tools.
Saxo Capital Markets (Classic account)
US$4
1%
ASX shares, Global shares, ETFs
Access 22,000+ stocks on 50+ exchanges worldwide
Low fees for Australian and global share trading, no inactivity fees, low currency conversion fee and optimised for mobile.
Superhero share trading
US$0
50 pips (US$0.50 for every AU$100 exchanged)
ASX shares, US shares, ETFs
Sign up & fund your account with A$100 or more and receive US$10 of Tesla stocks on Superhero. T&Cs apply.
Enjoy $0 brokerage on US stocks and buying ETFs as well as a flat $5 fee to trade Australian shares.
loading

Compare up to 4 providers

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.

Is it a good time to buy Gilead Sciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Gilead Sciences share growth calculator

US$

Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.

Gilead Sciences price performance over time

Historical closes compared with the last close of $62.83

1 week (2022-06-21) 3.83%
1 month (2022-05-26) -2.54%
6 months (2021-12-27) -13.78%
1 year (2021-06-28) -7.19%
2 years (2020-06-26) -15.74%
3 years (2019-06-28) -7.00%
5 years (2017-06-28) -12.64%

Is Gilead Sciences under- or over-valued?

Valuing Gilead Sciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Gilead Sciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Gilead Sciences's P/E ratio

Gilead Sciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 18x. In other words, Gilead Sciences shares trade at around 18x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Gilead Sciences's PEG ratio

Gilead Sciences's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.517. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Gilead Sciences's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Gilead Sciences's EBITDA

Gilead Sciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$13.2 billion (£10.8 billion).

The EBITDA is a measure of a Gilead Sciences's overall financial performance and is widely used to measure a its profitability.

Gilead Sciences financials

Revenue TTM US$27.5 billion
Operating margin TTM 40.5%
Gross profit TTM US$21.8 billion
Return on assets TTM 10.65%
Return on equity TTM 23.1%
Profit margin 16.43%
Book value 15.878
Market capitalisation US$79.8 billion

TTM: trailing 12 months

Gilead Sciences's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Gilead Sciences.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Gilead Sciences's total ESG risk score

Total ESG risk: 22.15

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Gilead Sciences's overall score of 22.15 (as at 01/01/2019) is pretty good – landing it in it in the 31st percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Gilead Sciences is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Gilead Sciences's environmental score

Environmental score: 0.53/100

Gilead Sciences's environmental score of 0.53 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Gilead Sciences is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Gilead Sciences's social score

Social score: 12.97/100

Gilead Sciences's social score of 12.97 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Gilead Sciences is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Gilead Sciences's governance score

Governance score: 7.65/100

Gilead Sciences's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Gilead Sciences is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Gilead Sciences's controversy score

Controversy score: 2/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Gilead Sciences scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Gilead Sciences has, for the most part, managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Gilead Sciences Inc was last rated for ESG on: 2019-01-01.

Total ESG score 22.15
Total ESG percentile 30.98
Environmental score 0.53
Environmental score percentile 2
Social score 12.97
Social score percentile 2
Governance score 7.65
Governance score percentile 2
Level of controversy 2

Gilead Sciences share dividends

39%

Dividend payout ratio: 39.29% of net profits

Recently Gilead Sciences has paid out, on average, around 39.29% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 4.63% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Gilead Sciences shareholders could enjoy a 4.63% return on their shares, in the form of dividend payments. In Gilead Sciences's case, that would currently equate to about $2.86 per share.

While Gilead Sciences's payout ratio might seem fairly standard, it's worth remembering that Gilead Sciences may be investing much of the rest of its net profits in future growth.

Gilead Sciences's most recent dividend payout was on 29 June 2022. The latest dividend was paid out to all shareholders who bought their shares by 14 June 2022 (the "ex-dividend date").

Have Gilead Sciences's shares ever split?

Gilead Sciences's shares were split on a 2:1 basis on 28 January 2013. So if you had owned 1 share the day before the split, the next day you would own 2 shares. This wouldn't directly have changed the overall worth of your Gilead Sciences shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Gilead Sciences shares which in turn could have impacted Gilead Sciences's share price.

Gilead Sciences share price volatility

Over the last 12 months, Gilead Sciences's shares have ranged in value from as little as US$55.9001 up to US$72.2839. A popular way to gauge a stock's volatility is its "beta".

Beta measures a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Gilead Sciences's is 0.3798. This would suggest that Gilead Sciences's shares are less volatile than average (for this exchange).

Gilead Sciences overview

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com.au:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com.au is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our Terms of Use, Disclaimer & Privacy Policy and Privacy & Cookies Policy.
Go to site